Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions

Select a cancer below for additional information on ORP active trials at NCCN Member Institutions.


Scott Plotkin, MDDana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer CenterPhase 2 study of neratinib for adolescents and adults with neurofibromatosis 2 and progressive NF2-related neoplasms: a sub-study of the INTUITT-NF2 platform-basket trial (NCT04374305)
Nguyen Tran, MDMayo Clinic Comprehensive Cancer CenterPhase 2 Study of FGFR4 Inhibitor Futibatinib in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Advanced or Metastatic Hepatocellular Carcinoma with FGF19 Expression After First-line Therapy
Namrata Vijayvergia, MDFox Chase Cancer CenterA Multi-Center Phase I trial of Neratinib and fam-trastuzumab deruxtecan in advanced refractory gastric cancer patients

Gynecological Cancers

Siqing Fu MD PhDThe University of Texas MD Anderson Cancer CenterA Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

Head and Neck Cancers

Aarti Bhatia, MD, MPHYale Cancer Center/Smilow Cancer HospitalSingle-Arm Phase II Trial of Dual Inhibition of EGFR with Afatinib and Cetuximab with Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck

Hematologic Cancers

Sanjay Mohan, MDThe University of Texas MD Anderson Cancer CenterPhase 2 Study of Decitabine and Cedazuridine in Combination with Venetoclax for AML Relapse after Allogenic Hematopoietic Cell Transplantation

Lung Cancer

Yasir Elamin, MDThe University of Texas MD Anderson Cancer CenterRandomized Phase II Trial of Osimertinib with or without Local Consolidation Therapy (LCT) for Patients with EGFR-mutant Metastatic NSCLC (NORTHSTAR)
Pasi Janne, MDDana-Farber/Brigham and Women's Cancer Center/ Massachusetts General HospitalA Phase 2 Study of Osimertinib in Combination with Selumetinib in EGFR Inhibitor Naïve Advanced EGFR Mutant Lung Cancer
Joseph Treat, MDFox Chase Cancer CenterTH-138: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, with or without atezolizumab in stage IV non-squamous NSCLC patients who harbor a sensitizing EGFR mutation or have never smoked


Martin McCarter, MDUniversity of Colorado Anschutz Medical CampusOral Decitabine/Cedazuridine (Invoqi) in Combination with Nivolumab as a Strategy to Enhance the Efficacy of Immune Checkpoint Blockade in Unresectable or Metastatic Mucosal Melanoma

Prostate Cancer

Gurkamal Chatta, MDRoswell Park Comprehensive Cancer CenterA Phase IB Clinical Trial: Improving Outcomes with Androgen Pathway Inhibitors by targeting DNA methyltransferase Activity